In the context of immunotherapy, the tumor-intrinsic NLRP3-heatshock protein 70 (HSP70) toll-like receptor 4 (TLR4) axis has been associated with disease hyper-progression and survival in patients undergoing anti-PD-1 immunotherapy [39]. The gene discussed is NLRP3; the disease is neoplasm.